Vidofludimus calcium

Drug Profile

Vidofludimus calcium

Alternative Names: IMU 838

Latest Information Update: 16 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator 4SC
  • Developer Immunic
  • Class Amides; Anti-inflammatories; Biphenyl compounds; Carboxylic acids; Cyclopentanes; Disease-modifying antirheumatics; Fluorobenzenes; Phenyl ethers; Small molecules
  • Mechanism of Action Dihydroorotate dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Crohn's disease

Most Recent Events

  • 17 Jan 2018 Immunic AG plans the CALDOSE-1 phase II trial for Ulcerative Colitis in Germany in early 2018 (NCT03341962),
  • 16 Jan 2018 USFDA approves IND application for IM 838 in Ulcerative colitis
  • 11 Jan 2018 Immunic Therapeutics plans a phase II trial (CALDOSE-2) for Crohn’s disease
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top